Biocompatible iron(<scp>iii</scp>) carboxylate metal–organic frameworks as promising RNA nanocarriers

Hidalgo, Tania; Alonso-Nocelo, Marta; Bouzo, Belén L.; Reimondez-Troitiño, Sonia; Redondo, Carmen Abuín; Fuente, María de la; Horcajada, Patricia

doi:10.1039/c9nr08127e

Cited by 55 publications

(37 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, results obtained with SNs-Lpx were superior to those recently published with miRNA145-loaded PLGA/PEI/HA nanoparticles in HTC-116 cells (11-fold increase), miRNA-145-loaded magnetic nanoparticles in AsPC-1cells (19-fold increase) and HPAF-II cells (4-fold increase), miRNA145-loaded cationic liposomes in HepG2 cells (9-fold increase), miRNA145 associated to a lentiviral vector in SW620 cells (8.2-fold increase), and miRNA145-loaded protamine nanocapsules in SW480 cells (33-fold increase) [15][16][17]49,50]. In relation to nanometric porous metal-organic frameworks (nanoMOFs), they show a similar efficiency in SW480 cells, superior to lipofectamine, as recently published by our group [51].…”

Section: Transfection Efficiencysupporting

confidence: 60%

Sphingomyelin-Based Nanosystems (SNs) for the Development of Anticancer miRNA Therapeutics

et al. 2020

View full text Add to dashboard Cite

Gene replacement therapy with oncosuppressor microRNAs (miRNAs) is a promising alternative to interfere with cancer progression. However, miRNAs are highly inefficient in a biological environment, hampering a successful translation to clinics. Nanotechnology can tackle this drawback by providing delivery systems able to efficiently deliver them to cancer cells. Thus, the objective of this work was to develop biocompatible nanosystems based on sphingomyelin (SM) for the intracellular delivery of miRNAs to colorectal cancer cells. We pursued two different approaches to select the most appropriate composition for miRNA delivery. On the one hand, we prepared sphingomyelin-based nanosystems (SNs) that incorporate the cationic lipid stearylamine (ST) to support the association of miRNA by the establishment of electrostatic interactions (SNs–ST). On the other hand, the cationic surfactant (DOTAP) was used to preform lipidic complexes with miRNA (Lpx), which were further encapsulated into SNs (SNs-Lpx). Restitution of miRNA145 levels after transfection with SNs-Lpx was related to the strongest anticancer effect in terms of tumor proliferation, colony forming, and migration capacity assays. Altogether, our results suggest that SNs have the potential for miRNA delivery to develop innovative anticancer therapies.

show abstract

Section: Transfection Efficiencysupporting

confidence: 60%

Sphingomyelin-Based Nanosystems (SNs) for the Development of Anticancer miRNA Therapeutics

et al. 2020

View full text Add to dashboard Cite

show abstract

“… 1 , 2 , 3 , 4 , 5 , 6 The ability to control particle size, 7 , 8 , 9 surface chemistry, 10 and internal porosity 11 , 12 has led to increasingly complex MOF-based materials. These have been designed to target specific cells 13 and organelles, 14 transport large specialized cargo such as oligonucleotides and proteins, 15 , 16 , 17 , 18 , 19 release these in response to specific stimuli, 20 , 21 and combine drug delivery with other techniques such as imaging 22 , 23 , 24 , 25 , 26 or photodynamic therapy. 27 , 28 Despite this diversification of material, the process of postsynthetic drug loading itself is often undercharacterized; cargo is often simply assumed to penetrate the porosity of the MOF despite potential competition from loading solvents.…”

Section: Introductionmentioning

confidence: 99%

Identifying Differing Intracellular Cargo Release Mechanisms by Monitoring In Vitro Drug Delivery from MOFs in Real Time

Μαρκοπούλου

Panagiotou

et al. 2020

Cell Reports Physical Science

View full text Add to dashboard Cite

“…Various other nucleotide@MOF delivery systems have been reported for other applications, such as the delivery of the gene‐editing tool CRISPR/CAS9, [ 129 ] siRNA@NCP, [ 127 ] ssDNA@IRMOF‐74(Ni), using a toxic metal, [ 130 ] , mRNA using UiO‐66(Zr), [ 131 ] and MIL‐100(Fe). [ 132 ] The delivery of mRNA using MIL‐100(Fe) in particular is promising due to its biocompatibility and its comparatively good stability in phosphate‐containing solutions.…”

Section: Mof Compositesmentioning

confidence: 99%

Metal–Organic Framework Composites for Theragnostics and Drug Delivery Applications

Osterrieth

Fairen‐Jimenez

2020

Biotechnology Journal

108

View full text Add to dashboard Cite

Among a plethora of nano‐sized therapeutics, metal‐organic frameworks (MOFs) have been some of the most investigated novel materials for, predominantly, cancer drug delivery applications. Due to their large drug uptake capacities and slow‐release mechanisms, MOFs are desirable drug delivery vehicles that protect and transport sensitive drug molecules to target sites. The inclusion of other guest materials into MOFs to make MOF‐composite materials has added further functionality, from externally triggered drug release to improved pharmacokinetics and diagnostic aids. MOF‐composites are synthetically versatile and can include examples such as magnetic nanoparticles in MOFs for MRI image contrast and polymer coatings that improve the blood‐circulation time. From synthesis to applications, this review will consider the main developments in MOF‐composite chemistry for biomedical applications and demonstrate the potential of these novel agents in nanomedicine. It is concluded that, although vast synthetic progress has been made in the field, it requires now to develop more biomedical expertise with a focus on rational model selection, a major comparative toxicity study, and advanced targeting techniques.

show abstract

Biocompatible iron(iii) carboxylate metal–organic frameworks as promising RNA nanocarriers

Abstract: Rapid cell-internalization of biocompatible RNA-loaded nanoMOFs leads to an effective in vitro gene activity while protects nucleic acids from degradation.

Cited by 55 publications

References 42 publications

Sphingomyelin-Based Nanosystems (SNs) for the Development of Anticancer miRNA Therapeutics

Sphingomyelin-Based Nanosystems (SNs) for the Development of Anticancer miRNA Therapeutics

Identifying Differing Intracellular Cargo Release Mechanisms by Monitoring In Vitro Drug Delivery from MOFs in Real Time

Metal–Organic Framework Composites for Theragnostics and Drug Delivery Applications

Contact Info

Product

Resources

About